

Complications and Functional Outcomes After Total Hip Arthroplasty and Total Knee Arthroplasty: Results From the Global Orthopaedic Registry (GLORY)

Fred Cushner, MD, Giancarlo Agnelli, MD, Gordon FitzGerald, PhD, and David Warwick, MD, FRCS (Ortho)

ABSTRACT

The Global Orthopaedic Registry (GLORY) has been designed to monitor a broad range of complications and outcomes that occur following total hip arthroplasty (THA) and total knee arthroplasty (TKA). GLORY provides global “real-world” data, in contrast to the data generated by the controlled conditions of clinical trials.

The results to date show an overall incidence of both in-hospital and post-discharge complications of approximately 7% in THA patients and 8% in TKA patients. The most common in-hospital complications in THA patients are fractures (0.6%) and deep vein thrombosis (DVT) (0.6%), whereas in TKA patients DVT (1.4%) and cardiac events (0.8%) are most common. The most common post-discharge complications in both THA and TKA patients are reoperation due to bleeding, wound necrosis, wound infection, or other causes; and DVT. Bleeding complications were less common than other adverse events in both groups (in-hospital rates of 0.48% and 0.83%, respectively). Functional outcomes improved after surgery in both groups, as expected. Younger patients and patients who had been discharged directly to their homes seemed to have the greatest improvement in functional outcome after surgery.

The Global Orthopaedic Registry (GLORY) has been designed not only to monitor practices in orthopedic surgery but also to provide insights into complications and functional outcomes resulting from such surgery.

Dr. Cushner is with the ISK Institute for Orthopaedics and Sports Medicine, New York, New York, USA.

Dr. Agnelli is with Sezione di Medicina Interna e Cardiovascolare, Perugia, Italy.

Dr. FitzGerald is with the Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Dr. Warwick is with Southampton University Hospital, Southampton, United Kingdom.

For correspondence, contact: Fred Cushner, MD, ISK Institute for Orthopaedics and Sports Medicine, 178 East 85th Street, New York, NY 10028, USA (tel, 212-434-4334; fax, 212-650-0895; e-mail, fcush@att.net).

Am J Orthop. 2010;39(9 Suppl):22-28. Copyright 2010, Quadrant HealthCom Inc. All rights reserved.

Data on outcomes after total hip arthroplasty (THA) or total knee arthroplasty (TKA) have been collected from clinical trials that assess individual devices or from country-specific registries. The first registries to be established were the Swedish THA and TKA registries.^{1,2} These, together with subsequent country-specific registries worldwide, have provided important information on the long-term outcomes following THA and TKA. Most registries focus on outcomes resulting from different types of implant and the factors that affect implant survival. As a result, they provide a valuable quality-improvement tool to identify inferior implants as early as possible,^{1,3} but they offer relatively little information about other complications and functional outcomes.

GLORY has been designed to monitor a broader range of complications and outcomes than those related solely to implant survival.⁴ As an international registry, it includes global, rather than country-specific or implant-specific, data. Data from GLORY can thus provide important insights into THA and TKA practices worldwide and also the incidence of different types of complications. Because of the worldwide nature of GLORY, some practice patterns, such as the relatively high prescription rate of low-molecular-weight heparin and the low rate of aspirin use for prophylaxis of venous thromboembolism (VTE) may not be representative of a US-specific population.

This paper reviews the incidence and nature of complications following THA or TKA as recorded in GLORY and compares these findings with those of previous studies.

METHODS

GLORY is a multinational, observational study that has been designed to examine treatment practices in patients undergoing major joint replacement surgery. The methodology has been described in full by Anderson and colleagues.⁵ The study was designed and is coordinated by the Center of Outcomes Research at the University of Massachusetts, USA, under the guidance of a Scientific Advisory Board. Full details of GLORY are available on the registry web site.⁴

A total of 156 surgeons have enrolled patients from 100 university-affiliated or community hospitals in 13 countries worldwide. Participating surgeons enrolled 15,020 patients who had undergone elective primary THA (6,695

Table I. Incidence of Complications Occurring in Hospital and After Discharge in GLORY

Complication	In-Hospital Complications		Additional Complications 3 Months Post-Surgery	
	THA (n = 6,695)	TKA (n = 8,325)	THA (n = 4,940)	TKA (n = 5,550)
One or more complications	486 (7.3%)	671 (8.1%)	332 (6.7%)	445 (8.0%)
Fracture	41 (0.6%)	8 (0.1%)	19 (0.4%)	10 (0.2%)
Deep vein thrombosis	40 (0.6%)	113 (1.4%)	49 (1.0%)	38 (0.7%)
Dislocation	34 (0.5%)	3 (0.1%)	39 (0.8%)	3 (0.1%)
Nerve palsy	33 (0.5%)	14 (0.2%)	19 (0.4%)	11 (0.2%)
Wound infection	29 (0.4%)	35 (0.4%)	43 (0.9%)	94 (1.7%)
Reoperation	27 (0.4%)	42 (0.5%)	56 (1.1%)	126 (2.3%)
Bleeding—delayed discharge/ Major bleeding*	21 (0.3%)	26 (0.3%)	4 (0.1%)	8 (0.1%)
Cardiac events	29 (0.4%)	50 (0.8%)	10 (0.2%)	18 (0.3%)
Pneumonia	14 (0.2%)	29 (0.5%)	ND	ND
Pulmonary embolism	7 (0.1%)	23 (0.3%)	6 (0.1%)	6 (0.1%)
Death	9 (0.1%)	16 (0.2%)	16 (0.3%)	7 (0.1%)
Other**	236 (3.5%)	325 (3.9%)	149 (3.0%)	263 (4.7%)

* Bleeding defined as "Bleeding-delayed discharge" for in-hospital complications and defined as "Major bleeding" for additional complications 3 months post-surgery

** Unspecified.

Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty; ND, no data.

Table II. Incidence of Bleeding in Hospital and 3 Months After Surgery

Bleeding Type	In-Hospital Bleeding		Additional Bleeding 3 Months Post-Surgery	
	THA (n = 6,695)	TKA (n = 8,325)	THA (n = 4,940)	TKA (n = 5,550)
Bleeding necessitating reoperation	2 (0.03%)	9 (0.11%)	1 (0.02%)	3 (0.06%)
Bleeding—delayed discharge	21 (0.31%)	26 (0.31%)	0	0
Hematoma requiring evacuation	7 (0.10%)	25 (0.30%)	1 (0.02%)	4 (0.07%)
Epidural hematoma	1 (0.01%)	1 (0.01%)	0	0
Gastrointestinal bleeding	3 (0.06%)	15 (0.25%)	0	0
Other bleeding during surgery	2 (0.04%)	0	0	0
Major bleeding	0	0	4 (0.08%)	8 (0.14%)
Readmission due to bleeding	0	0	2 (0.04%)	1 (0.02%)
Any	32 (0.48%)*	69 (0.83%)*	8 (0.16%)	16 (0.29%)

* Significantly different, $P = .01$

Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty.

patients) or TKA (8,325 patients) between June 2001 and December 2004; revision procedures were excluded. In-hospital data were collected for all patients, and 70% of patients were followed up after 3 months and/or 12 months to collect data on post-discharge outcomes.


Participating surgeons or trained study coordinators collected data using standard case report forms, which were sent to the scientific coordinating center for entry into the database and for subsequent analysis. Data quality control was monitored using standardized query logic. Out-of-range or illogical responses were queried on a quarterly basis, and corrections were faxed to the scientific coordinating center.

Approval of the study was obtained from local ethics committees or institutional review boards, as required. When required by the Ethics Review Committee at each hospital, signed informed consent was obtained from patients prior to their enrollment. Chi-square or Fisher's exact test was used to test for rate differences in different groups. Wilcoxon's ranked sum test or analysis of variance was used to test group differences between continuous variables.


GENERAL COMPLICATIONS

Previous studies have identified a broad range of complications following THA^{6,7} or TKA.⁸ These include delayed wound healing or wound dehiscence; renal and urinary complications; cardiovascular complications, VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE), myocardial infarction, or bleeding; and pneumonia and other respiratory complications.

The data from GLORY show a similar spectrum of complications (Table I). The overall incidence of both in-hospital and post-discharge complications was approximately 7% in THA patients and 8% in TKA patients. However, the nature of the recorded complications was similar in all countries and all types of hospitals. The incidence of in-hospital and post-discharge complications was similar in the United States and in the other participating countries in THA patients ($P = .32$ and $.60$ for in-hospital and post-discharge, respectively), but was slightly higher in other participating countries than in the United States in TKA patients ($P < .001$ for both in-hospital and post-discharge; Figure).



a. In-hospital



b. Post-discharge

Figure. Incidence of in-hospital and post-discharge complications following total hip arthroplasty and total knee arthroplasty in the United States (USA) and the other participating countries. Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty.

In THA patients, the most common in-hospital complications were fractures and DVT, both of which occurred in 0.6% of patients, whereas in TKA patients the most common in-hospital complications were DVT (1.4%) and cardiac events (0.8%). The most common post-discharge complications in both THA and TKA patients were reoperation due to bleeding, wound necrosis, wound infection, or other causes (1.1% and 2.3%, respectively), wound infections (0.9% and 1.7%, respectively), and DVT (1.0% and 0.7%, respectively). Some complications, such as myocardial infarction and pneumonia, were uncommon in both groups, reflecting the fact that THA and TKA are elective procedures that are mainly performed in healthy patients.

The relatively low incidence of reoperations reported in GLORY is of interest, given the higher incidence reported in the Swedish hip and knee registries. As noted earlier, these focus largely on implant survival as a major outcome and document the reasons for reoperation or revision.¹ Of 229,031 primary THAs that were performed between 1979 and 2003, reoperation was necessary in 26,111 (11.4%).² The most common reason for reoperation was aseptic loosening, which accounted for 60.6% of reoperations, followed by dislocation (10.7%), deep infection (8.3%), and fracture (6.8%).² Among patients undergoing knee arthroplasty (both TKA and unicompartmental arthroplasty), a total of 1,902 of 41,223 (4.6%) primary arthroplasties that were performed between 1988 and 1997 had been revised by the end of this period.⁸ The principal reason for revision (including revisions of arthroplasties

that were performed before 1988) was loosening, which accounted for 44% of procedures. Approximately 50% of revisions were performed within 4 years of the primary arthroplasty; in particular, revisions due to infection or patellar problems were more common during the first 45 months than they were after the first 45 months.⁹

The higher incidence of reoperations seen in the Swedish registry data, compared with the GLORY data, may reflect the shorter follow-up period in GLORY and the fact that since the time the Swedish registry was started (as early as 1979) practice has improved with type of implants, antibiotics, and so on. It is difficult to compare the rates of other complications in the Swedish and GLORY registries because GLORY reports all complications, whereas the Swedish registries report only those that lead to reoperation. For example, DVT and cardiac events are relatively frequent complications in GLORY (Table I), whereas these tend to be unreported in the Swedish registries as they would not lead to revision.

A further registry-based study, which was conducted in Iceland, has reported markedly higher rates of dislocations (5%) and cardiac or cerebrovascular complications (3.1%) among THA patients than those reported in GLORY (Table I).¹⁰ The incidence of wound infections (0.5%) and VTE, including both DVT and PE (1.5%), in this study were comparable with those in GLORY. However, as with the Swedish registries, these data are country-specific and, moreover, relate to a smaller patient population (548), who received a single type of implant.

BLEEDING

Comparisons of bleeding rates in studies of THA and TKA patients are complicated because the definitions of clinically important or major bleeding have varied considerably between trials.¹¹ In GLORY, clinically important bleeding has been defined as “bleeding that is recorded by the surgeon as being outside the range of ‘typical expected levels’ of bleeding following THA/TKA, or bleeding that is cited as the cause of prolonged hospital stay.” Clinically important bleeding included multiple types of bleeding (Table II), amongst others bleeding necessitating reoperation, bleeding-delayed discharge, and gastrointestinal bleeding. The incidence of such bleeding in GLORY was relatively

Table III. Incidence of Bleeding (Major or Minor) in Relation to Use of Thromboprophylaxis

	n (In-Hospital) / n (In-Hospital or 3 Month Post-Surgery Bleeding)	In-Hospital Bleeding	In-Hospital or 3 Month Post-Surgery Bleeding
LMWH alone	9,241/5,858	65 (0.7%)*	45 (0.8%)
Warfarin alone	4,148/1,431	14 (0.3%)*	9 (0.6%)
Both	485/308	8 (1.7%)	6 (2.0%)
Neither	1,146/563	14 (1.2%)	10 (1.8%)

* Significantly different, $P = .01$
Abbreviations: LMWH, low-molecular-weight heparin.

Table IV. Incidence of Venous Thromboembolism (DVT and PE) According to Patient Sex and Age

	DVT		PE	
	THA	TKA	THA	TKA
Total	1.6%	2.3%	0.24%	0.29%
Men	1.4%	1.6%	0.25%	0.32%
Women	1.7%	2.6%	0.25%	0.28%
Age < 65 years	1.4%	2.3%	0.23%	0.47%
Age ≥ 65 years	1.8%	2.2%	0.25%	0.21%

Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; THA, total hip arthroplasty; TKA, total knee arthroplasty.

low, both in THA patients (0.48% in hospital; 0.16% 3 months after surgery) and in TKA patients (0.83% and 0.29%, respectively; Table II). Some patients had both in-hospital bleeding and additional bleeding in the 3 months after surgery, so that overall, 29 of 4,940 THA patients (0.59%) experienced clinically important bleeding, compared with 59 of 5,550 (1.06%) TKA patients. Clinically important in-hospital bleeding, albeit rare, was significantly more common after TKA than after THA (0.83% vs 0.48%, respectively; $P = .01$, Table II). With this level of clinically important bleeding in GLORY, it was not possible to determine which factors were associated with an increased risk for bleeding. Blood transfusions were given to 57% of THA and 42% of TKA patients at a median volume of 600 mL (see also Waddell and colleagues¹² in this supplement for details on blood usage).

The results from GLORY are consistent with those of a recent systematic review,¹³ which included data from 71 trials, involving 32,433 patients. This review compared different thromboprophylactic regimens in patients undergoing major orthopedic surgery (THA, TKA, or hip-fracture surgery). Major bleeding occurred in 632 patients (1.95%) receiving thromboprophylaxis, of whom only 118 (0.4%) required surgical or medical intervention; only 5 cases of fatal bleeding were identified. The most common location of bleeding was the wound site, which accounted for 71% of major bleeding episodes; 7% of episodes occurred in the gastrointestinal tract, and the remainder at other sites.¹³

Impact of Thromboprophylaxis on Bleeding Risk

Major or minor bleeding can occur in a significant proportion of patients who are undergoing major orthopedic surgery, even in the absence of thromboprophylaxis. For example, in a meta-analysis of 52 trials of thromboprophylaxis, involving almost 11,000 THA patients, the total incidence of minor and major bleeding in placebo-treated patients was 3.0% and 0.6%, respectively.¹⁴

The GLORY population consisted of a large sample of THA and TKA patients, of whom almost all (99% in both groups) received some form of thromboprophylaxis. Approximately two-thirds of patients in each group received low-molecular-weight heparin (LMWH) and approximately 30% in each group received warfarin. As shown in Table III, the incidence of bleeding, either in

Table V. In-Hospital and Post-Discharge Mortality

	THA (n = 6,695)	TKA (n = 8,325)
Deaths in hospital	9 (0.1%)	16 (0.2%)
Deaths attributed to PE in hospital	0	2
Post-discharge deaths within 3 months of surgery*	16 (0.3%)	7 (0.1%)
Deaths attributed to PE post-discharge	1	0

* Median follow-up 3 months, range 1-18 months. Four additional TKA deaths occurred at 6-15 months post-surgery.

Abbreviations: PE, pulmonary embolism; THA, total hip arthroplasty; TKA, total knee arthroplasty.

hospital or at 3 months after discharge, was low in these patients (0.8% in LMWH-treated patients; 0.6% in warfarin-treated patients). Data from randomized controlled trials and meta-analyses have shown that prophylactic doses of vitamin-K antagonists, low-dose unfractionated heparin (UFH), and LMWH are associated with little or no increase in the risk of clinically significant bleeding.^{14,15} In the meta-analysis by Muntz and colleagues,¹³ the relative risk of major bleeding with UFH, compared with LMWH, was 1.52 (95% CI, 1.04–2.23). In addition, fondaparinux, a synthetic pentasaccharide, was also associated with an increased risk of major bleeding, compared with LMWH (Relative Risk, 1.52; 95% CI, 1.11–2.09).

In GLORY, in-hospital bleeding was significantly less common in warfarin-treated patients than in those receiving LMWH (0.3% vs 0.7%, respectively; $P = .01$). This might reflect the delayed onset of the anticoagulant effect of warfarin, as a result of which the therapeutic effect might not have been achieved in many patients until after discharge from hospital. Furthermore, owing to the nature of the GLORY registry, physician perceptions regarding the risk of bleeding may have influenced the decision as to which drug to give the patient.

VASCULAR COMPLICATIONS

Venous Thromboembolism

The GLORY data reflect the incidence of VTE in a real-world setting, in contrast to those data that are generated in the rigorously controlled conditions of clinical trials. Thromboprophylactic practices vary widely between hospitals, and they are fully documented in the registry. As shown in Table I, DVT (confirmed by venogram or ultrasound) was one of the most common in-hospital and delayed complications in both THA and TKA patients enrolled in GLORY. The incidence of VTE (DVT and PE) in different patient subgroups is shown in Table IV. The overall incidence of DVT in-hospital and post-discharge was higher in TKA patients than in THA patients (2.3% vs 1.6%, respectively). In patients undergoing TKA, the incidence was higher in women than in men and was similar in older (age ≥ 65 years) and younger (age < 65 years) patients. In THA patients, the incidence of DVT was similar irrespective of sex or age. The incidence of

Table VI. Functional Outcomes After THA or TKA, Assessed by Means of the WOMAC and SF-8 Questionnaires, According to Patient Characteristics

	WOMAC				SF-8 Mental				SF-8 Physical			
	<i>n</i>	Pre	Post	Diff	<i>n</i>	Pre	Post	Diff	<i>n</i>	Pre	Post	Diff
THA	2662	42.7	76.6	33.9	2546	47.0	51.7	4.8	2546	31.4	43.8	12.4
TKA	2987	46.5	72.8	26.3	2802	48.8	51.1	2.2	2802	32.7	42.4	9.8
<i>P</i> value		<.0001	<.0001	<.0001		<.0001	.004	<.0001		<.0001	<.0001	<.0001
Male	2060	48.0	76.7	28.8	1939	50.0	52.6	2.7	1939	33.2	44.3	11.1
Female	3489	42.8	73.3	30.6	3311	46.7	50.6	3.9	3311	31.4	42.5	11.1
<i>P</i> value		<.0001	<.0001	.001		<.0001	<.0001	<.0001		<.0001	<.0001	.94
Age < 65 years	2156	43.2	74.5	31.4	2059	47.8	51.6	3.8	2059	31.7	43.5	11.8
Age ≥ 65 years	3459	45.7	74.6	28.9	3256	48.0	51.2	3.2	3256	32.3	42.8	10.5
<i>P</i> value		<.0001	.92	<.0001		.53	.07	.03		.01	.005	<.0001
Home Rehabilitation/	3251	45.2	75.6	30.4	3084	48.0	51.7	3.7	3084	32.5	44.1	11.6
Other	2266	43.9	73.1	29.2	2141	47.9	50.9	3.1	2141	31.4	41.7	10.3
<i>P</i> value		.005	<.0001	.01		.79	.003	.03		<.0001	<.0001	<.0001

Abbreviations: Diff, difference in mean scores; Post, mean 3-months postoperative score; Pre, mean preoperative score; SF-8, SF-8 Health Survey; THA, total hip arthroplasty; TKA, total knee arthroplasty; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

PE was 0.2% to 0.3% in all subgroups except in men who underwent TKA and TKA patients under 65 years of age, in which the incidences of PE were slightly higher at 0.32% and 0.47%, respectively.

Similar findings were reported in a review of the epidemiology of VTE in patients undergoing major orthopedic surgery.¹⁶ The data from 7 studies of pharmacologic or mechanical thromboprophylaxis in patients undergoing THA, TKA, or hip-fracture surgery suggest that the incidence of DVT is approximately 2.5% and that the risks of nonfatal or fatal PE occurring are approximately 1% and up to 0.4%, respectively.¹⁶

A further study has used data from the California Patient Discharge Series (a registry of discharge data from all nonfederal licensed hospitals in California) to investigate the incidence of symptomatic VTE in patients undergoing a variety of surgical procedures.¹⁷ The incidence of VTE at 91 days in patients undergoing THA or TKA was 2.4% and 1.7%, respectively, of which 1.8% and 0.8% of cases, respectively, occurred after discharge. It should be noted, however, that information about the use of thromboprophylaxis was not available in this study.

A recent report has described the incidence of PE in 3,954 patients undergoing THA, TKA, or hip-fracture surgery, who were included in a prospective registry in Southern Norway between 1989 and 1998.¹⁸ All patients received thromboprophylaxis with LMWH for about 10 days until discharge. A total of 50 cases (1.3%) of nonfatal PE were identified. Importantly, the incidence of PE remained elevated for at least 2 to 3 months after surgery in patients undergoing THA and for several weeks after surgery in TKA patients. This persistent risk, despite the use of thromboprophylaxis, has been attributed to the fact that risk factors for VTE may be present for longer than the normal period of thromboprophylaxis. Extended-duration

thromboprophylaxis, which continued for up to 35 days after surgery, has been shown to reduce still further the risk of VTE after THA but not TKA.^{19,20}

Mortality Associated With Venous Thromboembolism

Pulmonary embolism has been reported to account for approximately 10% of in-hospital deaths,^{21,22} making VTE a major cause of mortality. Deaths that occurred either in hospital or post-discharge in the GLORY population are summarized in Table V. Overall, 25 of 6,695 (0.4%) THA patients and 23 of 8,325 (0.3%) TKA patients died in hospital or within 3 months after discharge, of whom 3 were believed to have died as a result of PE.

This low mortality rate is in marked contrast to data from the Norwegian Arthroplasty Register, which reported a 6% incidence of vascular death within 60 days after THA.²³ The mortality rate associated with PE or pulmonary infarction was 0.92%, and that associated with DVT was 0.28%. These higher rates, compared with the current GLORY results, may reflect improvements in surgical and prophylaxis techniques over the years.

Low rates of cardiac events occurred in the GLORY population, with 0.4% and 0.8% of THA and TKA patients, respectively, experiencing a cardiac complication.

FUNCTIONAL OUTCOMES

GLORY used a general health questionnaire, the SF-8 Health Survey (SF-8), and a disease-specific health questionnaire, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to assess functional outcomes after THA and TKA. The SF-8 is an alternative form of the widely used SF-36 quality-of-life (QOL) questionnaire, which uses a single question to measure each of the 8 SF-36 domains (physical function, social function, role-emotional,

role-physical, bodily pain, general health, mental health, and vitality). The WOMAC is a self-administered questionnaire that assesses pain, stiffness, and physical function. Both the SF-36 and WOMAC have been shown to be valid tools to assess outcomes after THA.²⁴

Table VI summarizes changes in SF-8 and WOMAC scores following THA or TKA in the GLORY population. Both measures showed, as expected, marked improvements after surgery. THA patients showed significantly lower scores before surgery than TKA patients, indicating that these patients experienced more pain and disability, and scores improved after surgery to a significantly ($P < .001$) greater extent in THA patients than in TKA patients. The WOMAC and SF-8 mental scores were significantly ($P < .0001$) lower in women than in men prior to and after surgery, although they improved to a significantly greater extent in women ($P = .0001$ for WOMAC; $P < .0001$ for SF-8 mental). Improvements in all scores after surgery were significantly lower in older patients (aged ≥ 65 years) than in younger patients, possibly reflecting the impact of comorbidity in older patients. Significantly greater improvements were also seen in patients who had been discharged to their homes rather than to rehabilitation facilities.

The WOMAC scores that were reported postoperatively are similar to those reported at 2 and 3 years after surgery in the Swedish National Total Hip Arthroplasty Register (a mean score of 74 at both time points).²⁵ This registry is also consistent with the GLORY data in that men showed higher postoperative QOL scores, as measured by the SF-36 questionnaire, than women.²⁶

The finding in GLORY that patients ≥ 65 years showed poorer improvements in functional outcomes than younger patients is in contrast to a previous study in 454 patients undergoing THA or TKA.²⁷ In this study, there were no significant differences between the improvements in WOMAC and SF-36 scores after surgery in patients aged 55 to 79 years and in those aged ≥ 80 years. Similarly, the finding in the present study that patients who had been discharged to their homes had higher QOL scores than those who had been discharged to rehabilitation facilities is at variance with those of a previous study involving 96 total arthroplasty patients.²⁸ In the latter study, there were no significant differences in outcome scores between patients who had been discharged to a subacute rehabilitation program and those who had been discharged directly to their homes with physical therapy follow-up. These differences may reflect the impact of sample size: as a result of the large number of patients enrolled in GLORY, this study can more easily identify patient-related factors affecting functional outcomes.

CONCLUSIONS

Although a variety of complications have been reported to occur after THA or TKA, the GLORY data show that the incidence of major complications is low. The most common complications included reoperations, infections, DVT, and (in THA patients) dislocations. It is notable that clinically important bleeding was

rare in the large sample of THA or TKA patients, essentially all of whom were given thromboprophylaxis.

The finding that DVT occurred in up to 1.4% of patients enrolled in GLORY shows that VTE remains an important potential complication of THA and TKA, despite the widespread use of thromboprophylaxis. This problem may be, at least partly, overcome by extending the duration of prophylaxis for up to 35 days after surgery, as has been shown to be effective in THA patients.^{19,20}

The data from GLORY show that the functional outcomes after THA or TKA may depend on the patient's characteristics. Although total arthroplasty can markedly improve patients' functioning and general well-being, the greatest benefits seem to be achieved in younger patients and in patients who have been discharged directly to their homes.

In conclusion, GLORY provides contemporary data on outcomes that occur after THA or TKA; these data are derived from a global, real-world setting that clinical trials are unable to reproduce as the inclusion and exclusion criteria are limiting. GLORY has been able to recruit a large and diverse patient population, and hence it was able to identify factors affecting outcomes that may not be apparent in clinical trials. It is notable, however, that the physicians in GLORY prescribe aspirin for VTE prophylaxis less frequently than has been shown in other studies.²⁹

AUTHOR'S DISCLOSURE STATEMENT AND ACKNOWLEDGMENTS

GLORY is supported by an unrestricted educational grant from sanofi-aventis and is coordinated by the Center for Outcomes Research at the University of Massachusetts Medical School, Worcester, MA. Dr. Cushner is a consultant for sanofi-aventis, Bayer, and Astellas. The other authors report no actual or potential conflict of interest in relation to this article.

REFERENCES

- Robertsson O, Lewold S, Knutson K, Lidgren L. The Swedish Knee Arthroplasty Project. *Acta Orthop Scand.* 2000;71(1):7-18.
- The Swedish National Hip Arthroplasty Register Annual Report 2003. Department of Orthopaedics, Sahlgrenska University Hospital, May 2004. Available at: <http://www.jru.orthop.gu.se>. Accessed August 2005.
- Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SE. The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. *Acta Orthop Scand.* 2000;71(4):337-353.
- The Center for Research Outcomes. The Global Orthopaedic Registry (GLORY). Available at: www.outcomes.org. Accessed August 2005.
- Anderson FA Jr. Overview of the Global Orthopaedic Registry (GLORY). *Am J Orthop.* 2010;39(9 Suppl):2-4.
- Saleh KJ, Kassim R, Yoon P, Vorlicky LN. Complications of total hip arthroplasty. *Am J Orthop.* 2002;31(8):485-488.
- Thompson R, Kane RL, Gromala T, et al. Complications and short-term outcomes associated with total hip arthroplasty in teaching and community hospitals. *J Arthroplasty.* 2002;17(1):32-40.
- Frosch P, Decking J, Theis C, Drees P, Schoellner C, Eckardt A. Complications after total knee arthroplasty: a comprehensive report. *Acta Orthop Belg.* 2004;70(6):565-569.
- Robertsson O, Knutson K, Lewold S, Lidgren L. The Swedish Knee Arthroplasty Register 1975-1997: an update with special emphasis on 41,223 knees operated on in 1988-1997. *Acta Orthop Scand.* 2001;72(5):503-513.

Complications and Functional Outcomes After Total Hip Arthroplasty and Total Knee Arthroplasty

10. Franklin J, Robertsson O, Gestsson J, Lohmander LS, Ingvarsson T. Revision and complication rates in 654 Exeter total hip replacements, with a maximum follow-up of 20 years. *BMC Musculoskelet Disord*. 2003;4:6. Available at: <http://www.biomedcentral.com/1471-2474/4/6>. Accessed August 2005.
11. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):S287-S310.
12. Waddell J, Johnson K, Hein W, Raabe J, FitzGerald G, Turibio F. Orthopedic practice in total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). *Am J Orthop*. 2010;39(9 Suppl):5-13.
13. Muntz J, Scott DA, Lloyd A, Egger M. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. *Int J Technol Assess Health Care*. 2004;20(4):405-414.
14. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg Am*. 2000;82(7):929-938.
15. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. *J Thromb Haemost*. 2004;2(7):1058-1070.
16. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. *Am J Health Syst Pharm*. 2001;58(Suppl 2):S4-S13.
17. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. *Thromb Haemost*. 2003;90(3):446-455.
18. Dahl OE, Gudmundsen TE, Bjørnå BT, Solheim DM. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients. *Acta Orthop Scand*. 2003;74(3):299-304.
19. Comp PC, Spiro TE, Friedman RJ, et al; and the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *J Bone Joint Surg Am*. 2001;83(3):336-345.
20. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. *Arch Intern Med*. 2000;160(14):2208-2215.
21. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. *Br J Surg*. 1991;78(7):849-852.
22. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? *J R Soc Med*. 1989;82(4):203-205.
23. Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. *Acta Orthop Scand*. 2002;73(4):392-399.
24. Söderman P, Malchau H. Validity and reliability of Swedish WOMAC osteoarthritis index. A self-administered disease-specific questionnaire (WOMAC) versus generic instruments (SF-36 and NHP). *Acta Orthop Scand*. 2000;71(1):39-46.
25. Söderman P, Malchau H, Herberts P, Zügner R, Regné H, Garellick G. Outcome after total hip arthroplasty. Part II. Disease-specific follow-up and the Swedish National Total Hip Arthroplasty Register. *Acta Orthop Scand*. 2001;72(2):113-119.
26. Söderman P, Malchau H, Herberts P. Outcome after total hip arthroplasty. Part I. General health evaluation in relation to definition of failure in the Swedish National Total Hip Arthroplasty Register. *Acta Orthop Scand*. 2000;71(4):354-359.
27. Jones CA, Voaklander DC, Johnston DW, Suarez-Almazor ME. The effect of age on pain, function, and quality of life after total hip and knee arthroplasty. *Arch Intern Med*. 2001;161(3):454-460.
28. Kelly MH, Ackerman RM. Total joint arthroplasty: a comparison of postacute settings on patient functional outcomes. *Orthop Nurs*. 1999;18(5):75-84.
29. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. *J Arthroplasty*. 2001;16(6):679-688.